Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 12/20 | 0.43 |
| ▸ | BECN1 | Q14457 | 8/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213436 | 0.90 | CYP17A1 (0.43) | CHRM1CYP17A1SREBF2PSMB8PRKDC | |
| SCHEMBL2216214 | 0.85 | CYP17A1 (0.41) | CHRM1CYP17A1PSMB8HDAC3HDAC1 | |
| SCHEMBL2215485 | 0.85 | PLAU (0.42) | CHRM1CYP17A1 | |
| SCHEMBL2216413 | 0.85 | CYP17A1 (0.49) | CYP17A1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2214171 | 0.85 | NAMPT (0.40) | BCL2BECN1CYP17A1HDAC1 | |
| SCHEMBL2213283 | 0.83 | PLG (0.42) | BCL2BECN1CHRM1CYP17A1 | |
| SCHEMBL2879548 | 0.80 | KDR (0.43) | — | |
| SCHEMBL2213704 | 0.80 | SIRT2 (0.43) | CYP17A1SREBF2 | |
| SCHEMBL2214996 | 0.80 | ESR2 (0.41) | HDAC8 | |
| SCHEMBL2214567 | 0.77 | HDAC1 (0.53) | HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797096-B1 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7745446-B2 | Pyrazolo[1,5-c]pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | ALTANA PHARMA AG (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254046-A1 | Novel Pyrazolopyrimidines | MCL1, RARS2, CDK4 | BCL2 45/4885BECN1 2073/4885CHRM1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.